G1 Therapeutics, Inc.

FREE EMAIL WATCHDOG

Get free email notifications about news in G1 Therapeutics, Inc..

The service is free and you can unsubscribe at any time.

General | People (57) | Filings (59) | Investment rounds (8) | Stock | News

Industry: PHARMACEUTICAL PREPARATIONS [2834]

CIK Number: 0001560241
IRS Number: 263648180

G1 Therapeutics, Inc. is a publicly traded company

Trading symbol: GTHX

G1 Therapeutics, Inc. is on the market more than 5 years.

News

2017-08-14

Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 ...
Nasdaq
Boxer Capital, LLC initiated holdings in G1 Therapeutics Inc. The purchase prices were between $15 and $19.14, with an estimated average price of $17.5.

2017-08-14

Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 ...
GuruFocus.com
Investment company Boxer Capital, LLC buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term Futures TM ETN, La Jolla Pharmaceutical Co, Sunesis Pharmaceuticals Inc, Seattle Genetics Inc, sells Clovis Oncology Inc, Blueprint ...

2017-08-09

G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent ...
GlobeNewswire (press release)
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today reported financial results for the quarter ended June 30, 2017, and provided an update on its ...

2017-08-08

G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference
Nasdaq
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview ...

2017-08-03

G1 Therapeutics Makes Key Appointments to Management Team
GlobeNewswire (press release)
RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the appointments of Terry Murdock as Senior Vice President, Development Operations, ...

2017-08-01

G1 Therapeutics, Inc. (Nasdaq: GTHX) to Ring The Nasdaq Stock Market Closing Bell
Nasdaq
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer, will visit the Nasdaq MarketSite in Times Square.

2017-07-27

G1 Therapeutics to Ring Nasdaq Stock Market Closing Bell on Wednesday, August ...
Nasdaq
RESEARCH TRIANGLE PARK, N.C., July 27, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Wednesday, ...
G1 THERAPEUTICS (GTHX) Expected to Announce Earnings of -$0.68 Per Share - The Cerbat Gem

G1 Therapeutics, Inc. address

79 T.W. ALEXANDER DRIVE
4501 RESEARCH COMMONS, SUITE 100
RESEARCH TRIANGLE PARK
27709

G1 Therapeutics, Inc. address

P. O. BOX # 110341
RESEARCH TRIANGLE PARK
27709

G1 Therapeutics, Inc. address

79 T.W. ALEXANDER DRIVE
4501 RESEARCH COMMONS, SUITE 100
RESEARCH TRIANGLE PARK
27709

Former name

Former name of this company was G-Zero Therapeutics, Inc., date of change: 2012-10-12.

Company jurisdiction

DELAWARE

Entity type

Corporation

Earliest known filing

October 2012

Latest known filing

August 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

G1 Therapeutics, Inc. has 59 filings. View G1 Therapeutics, Inc. filings.

Quarterly Reports

Latest company events

Investment Rounds

G1 Therapeutics, Inc. recieved 8 investments.

People

We have found 57 people related to G1 Therapeutics, Inc..

Similar companies

G1 EXECUTION SERVICES, LLC, G10-Rosseau Special Situations Fund (US) LP, G14M2 HHC, L.L.C., G1 Enterprises, LLC, G1R Florida, LLC, G1R Mass, LLC